Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04967170 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus
A Phase 1 study of Vulvar Lichen Sclerosus, sponsored by Jennifer R. Arthurs.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04967170: Active Phase 1 study of Vulvar Lichen Sclerosus, sponsored by Jennifer R. Arthurs.
NCT04967170 is a Phase 1 study of Vulvar Lichen Sclerosus that is active but no longer recruiting, run by Jennifer R. Arthurs. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04967170, a Phase 1 study of Vulvar Lichen Sclerosus, is active but no longer recruiting, sponsored by Jennifer R. Arthurs.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus.
Primary Outcome
Number of adverse events reported
Conditions Studied
Interventions
- OTHER Sham Procedure
- BIOLOGICAL Autologous Platelet-Rich Plasma (PRP)
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2026-06-02 |
| Phase | Phase 1 |
What the registry record for NCT04967170 still lists
NCT04967170 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Vulvar Lichen Sclerosus appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT04967170 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04967170 about?
NCT04967170 is a clinical study titled "A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus". The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus.
What is the current status of trial NCT04967170?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-01-19. Estimated completion is 2026-06-02.
What conditions does trial NCT04967170 study?
This clinical trial studies the following conditions: Vulvar Lichen Sclerosus.
What interventions are being tested in trial NCT04967170?
The interventions under investigation include: Sham Procedure (OTHER), Autologous Platelet-Rich Plasma (PRP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04967170?
This trial is sponsored by Jennifer R. Arthurs, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04967170 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vulvar Lichen Sclerosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04967170's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI